Compare Asana Inc. (ASAN) vs DexCom, Inc. (DXCM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Asana Inc. vs DexCom, Inc. — how do they compare? Asana Inc. trades at $7.36 (market cap $1.69B), while DexCom, Inc. trades at $75 (market cap $28.93B). The key difference: DexCom, Inc. is far larger — about 17.1× Asana Inc.'s market cap, and DexCom, Inc. is trading nearer its 52-week high, Asana Inc. nearer its low. Which is the better fit depends on your goals.
| ASAN | DXCM | |
|---|---|---|
Market Cap | $1.69B | $28.93B |
Sector | Consumer Cyclical | Health |
52-Week High | $15.35 | $89.53 |
52-Week Low | $5.46 | $54.84 |
Enterprise Value | $1.51B | $27.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Asana (ASAN) trades at $7.33, down 0.54% with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue growth from $378M in 2022 to $724M in 2025, though net losses persist. Recent Q1 2027 earnings beat expectations at $0.10 per share, and strategic acquisitions like StackAI enhance AI capabilities. Analyst consensus is mixed with 42% buy ratings and a $9.86 price target, representing 35% upside from current levels.
The outlook balances growth potential against profitability challenges. Positive catalysts include FedRAMP authorization for government contracts and AI innovation, but risks stem from intense competition with Microsoft and decelerating revenue growth. Cash flow turned positive in 2025, yet negative margins and high valuation multiples require careful monitoring for sustained improvement.
DXCM trades at $74.96, up 2.66% today, with strong technical momentum as price approaches resistance near $76. The company demonstrates robust fundamentals with revenue growth from $2.9B in 2022 to $4.7B in 2025 and expanding net margins to 17.93%. Recent FDA clearance for pediatric Stelo CGM and positive CONNECT trial results support growth in the non-insulin diabetes market.
Outlook remains positive with 80% analyst buy ratings and $83.78 consensus target, though risks include GLP-1 drug competition and execution in expanding beyond insulin-dependent patients. Earnings beat expectations in three consecutive quarters, with Q2 2026 results anticipated July 30, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Asana Inc.
Asana Inc is a software company. The company provides a platform for work management that helps teams orchestrate work, from daily tasks to cross-functional strategic initiatives. It helps plan marketing campaigns, streamlines processes, manages sales, and manage product launches. Also, the company provides project management and workflow management solutions.
Read more on ASAN →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
